FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Veterinary research2008; 39(3); 21; doi: 10.1051/vetres:2007062

Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host.

Abstract: In the horse, conventional inactivated or subunit vaccines against equine influenza virus (EIV) induce a short-lived antibody-based immunity to infection. Alternative strategies of vaccination have been subsequently developed to mimic the long-term protection induced by natural infection with the virus. One of these approaches is the use of immune-stimulating complex (ISCOM)-based vaccines. ISCOM vaccines induce a strong antibody response and protection against influenza in horses, humans, and a mouse model. Cell-mediated immunity (CMI) has been demonstrated in humans and mice after ISCOM vaccination, but rarely investigated in the horse. The aim of this study was to evaluate EIV-specific immune responses after intra-muscular vaccination with an ISCOM-EIV vaccine (EQUIP F) containing both equine influenza H7N7 (A/eq/Newmarket/77) and H3N8 (A/eq/Borlänge/91 and A/eq/Kentucky/98) strains. The antibody response was measured by single radial haemolysis (SRH) assay using different H3N8 EIV strains. Stimulation of type-1 immunity was evaluated with a recently developed method that measures EIV-specific IFNgamma synthesis by peripheral blood lymphocytes (PBL). The protective efficacy of this ISCOM-based vaccine against challenge infection with a recent equine influenza (H3N8; A/eq/South Africa/4/03) strain was also evaluated. Vaccinated ponies developed elevated levels of EIV-specific SRH antibody and increased percentage of EIV-specific IFNgamma(+) PBL, whereas these responses were only detected after challenge infection in unvaccinated control ponies. Vaccinates showed minimal signs of disease and did not shed virus when challenged shortly after the second immunisation. In conclusion, evidence of type-1 immunity induced by an ISCOM-based vaccine is described for the first time in horses.
Get Full Text
Publication Date: 2008-02-07 PubMed ID: 18252187DOI: 10.1051/vetres:2007062Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Randomized Controlled Trial

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study presented is focused on the effectiveness of an immune-stimulating complex (ISCOM)-based vaccine against equine influenza virus (EIV) in horses. The researchers found that this vaccine successfully induced a strong antibody response and limited disease symptoms, furthermore demonstrating this is the first evidence of type-1 immunity triggered by an ISCOM-based vaccine in horses.

Overview of the Research

  • Equine influenza virus (EIV) is a significant disease in horses. This research focuses on developing a more effective means of vaccination against EIV.
  • The conventional inactivated or subunit vaccines only provide a short-lived immunity to the virus, which has led to the exploration of more potent and long-lasting alternatives. The ISCOM-based vaccine is one of those alternatives.
  • ISCOM-based vaccines have been known to induce a strong antibody response. The immune responses to these vaccines, especially cell-mediated immunity (CMI), haven’t been thoroughly investigated in horses before this study.

Methods

  • The researchers evaluated the EIV-specific immunity in horses after intramuscular vaccination.
  • The ISCOM-EIV vaccine used contained both H7N7 and H3N8 strains of equine influenza.
  • The antibody response was measured by single radial haemolysis (SRH) assay using different H3N8 EIV strains.
  • Type-1 immunity was assessed through a method that measures EIV-specific IFNgamma synthesis by peripheral blood lymphocytes (PBL).
  • The protective efficacy of the vaccine was also evaluated against a recent equine influenza strain.

Results and Findings

  • Vaccinated ponies demonstrated elevated levels of EIV-specific SRH antibody and increased percentage of EIV-specific IFNgamma(+) PBL. These responses were only detected after infection challenge in unvaccinated control ponies.
  • The vaccinated ponies showed minimum signs of disease and did not shed the virus after the second immunisation, indicating the protective efficacy of the ISCOM-based vaccine.

Conclusion

  • The result of this study brought out the first evidence of type-1 immunity induced by an ISCOM-based vaccine in horses.

This research suggests that this ISCOM-based vaccine can be a successful fresh approach against equine influenza by inducing strong and potentially longer-lasting immunity in horses.

Cite This Article

APA
Paillot R, Grimmett H, Elton D, Daly JM. (2008). Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host. Vet Res, 39(3), 21. https://doi.org/10.1051/vetres:2007062

Publication

Veterinary research
ISSN: 0928-4249
NlmUniqueID: 9309551
Country: England
Language: English
Volume: 39
Issue: 3
Pages: 21

Researcher Affiliations

Paillot, Romain
  • Animal Health Trust, Centre for Preventive Medicine, Lanwades Park, Newmarket, Suffolk, CB8 7UU, UK. romain.paillot@aht.org.uk
Grimmett, Humphrey
    Elton, Debra
      Daly, Janet M

        MeSH Terms

        • Animals
        • Antibodies, Viral / biosynthesis
        • CD8-Positive T-Lymphocytes / metabolism
        • Horse Diseases / blood
        • Horse Diseases / immunology
        • Horse Diseases / prevention & control
        • Horses
        • Influenza A Virus, H3N8 Subtype / immunology
        • Influenza A Virus, H3N8 Subtype / pathogenicity
        • Influenza Vaccines / therapeutic use
        • Interferon-gamma / biosynthesis
        • Orthomyxoviridae Infections / prevention & control
        • Orthomyxoviridae Infections / veterinary
        • Treatment Outcome
        • Vaccination / veterinary

        Citations

        This article has been cited 17 times.
        1. Carnet F, Perrin-Cocon L, Paillot R, Lotteau V, Pronost S, Vidalain PO. An inventory of adjuvants used for vaccination in horses: the past, the present and the future. Vet Res 2023 Mar 2;54(1):18.
          doi: 10.1186/s13567-023-01151-3pubmed: 36864517google scholar: lookup
        2. Akache B, Stark FC, Agbayani G, Renner TM, McCluskie MJ. Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines. Methods Mol Biol 2022;2412:179-231.
          doi: 10.1007/978-1-0716-1892-9_9pubmed: 34918246google scholar: lookup
        3. Oladunni FS, Oseni SO, Martinez-Sobrido L, Chambers TM. Equine Influenza Virus and Vaccines. Viruses 2021 Aug 20;13(8).
          doi: 10.3390/v13081657pubmed: 34452521google scholar: lookup
        4. Reemers S, van Bommel S, Cao Q, Sutton D, van de Zande S. Protection against the New Equine Influenza Virus Florida Clade I Outbreak Strain Provided by a Whole Inactivated Virus Vaccine. Vaccines (Basel) 2020 Dec 21;8(4).
          doi: 10.3390/vaccines8040784pubmed: 33371484google scholar: lookup
        5. Reemers S, Sonnemans D, Horspool L, van Bommel S, Cao Q, van de Zande S. Determining Equine Influenza Virus Vaccine Efficacy-The Specific Contribution of Strain Versus Other Vaccine Attributes. Vaccines (Basel) 2020 Sep 3;8(3).
          doi: 10.3390/vaccines8030501pubmed: 32899189google scholar: lookup
        6. Entenfellner J, Gahan J, Garvey M, Walsh C, Venner M, Cullinane A. Response of Sport Horses to Different Formulations of Equine Influenza Vaccine. Vaccines (Basel) 2020 Jul 10;8(3).
          doi: 10.3390/vaccines8030372pubmed: 32664411google scholar: lookup
        7. Cullinane A, Gahan J, Walsh C, Nemoto M, Entenfellner J, Olguin-Perglione C, Garvey M, Huang Fu TQ, Venner M, Yamanaka T, Barrandeguy M, Fernandez CJ. Evaluation of Current Equine Influenza Vaccination Protocols Prior to Shipment, Guided by OIE Standards. Vaccines (Basel) 2020 Feb 29;8(1).
          doi: 10.3390/vaccines8010107pubmed: 32121419google scholar: lookup
        8. Dilai M, Piro M, El Harrak M, Fougerolle S, Dehhaoui M, Dikrallah A, Legrand L, Paillot R, Fassi Fihri O. Impact of Mixed Equine Influenza Vaccination on Correlate of Protection in Horses. Vaccines (Basel) 2018 Oct 4;6(4).
          doi: 10.3390/vaccines6040071pubmed: 30287762google scholar: lookup
        9. Singh RK, Dhama K, Karthik K, Khandia R, Munjal A, Khurana SK, Chakraborty S, Malik YS, Virmani N, Singh R, Tripathi BN, Munir M, van der Kolk JH. A Comprehensive Review on Equine Influenza Virus: Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies. Front Microbiol 2018;9:1941.
          doi: 10.3389/fmicb.2018.01941pubmed: 30237788google scholar: lookup
        10. Paillot R, Garrett D, Lopez-Alvarez MR, Birand I, Montesso F, Horspool L. The Immunity Gap Challenge: Protection against a Recent Florida Clade 2 Equine Influenza Strain. Vaccines (Basel) 2018 Jul 2;6(3).
          doi: 10.3390/vaccines6030038pubmed: 30004410google scholar: lookup
        11. Francica JR, Zak DE, Linde C, Siena E, Johnson C, Juraska M, Yates NL, Gunn B, De Gregorio E, Flynn BJ, Valiante NM, Malyala P, Barnett SW, Sarkar P, Singh M, Jain S, Ackerman M, Alam M, Ferrari G, Salazar A, Tomaras GD, O'Hagan DT, Aderem A, Alter G, Seder RA. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Adv 2017 Nov 28;1(25):2329-2342.
          doi: 10.1182/bloodadvances.2017011411pubmed: 29296883google scholar: lookup
        12. Paillot R, Rash NL, Garrett D, Prowse-Davis L, Montesso F, Cullinane A, Lemaitre L, Thibault JC, Wittreck S, Dancer A. How to Meet the Last OIE Expert Surveillance Panel Recommendations on Equine Influenza (EI) Vaccine Composition: A Review of the Process Required for the Recombinant Canarypox-Based EI Vaccine. Pathogens 2016 Nov 25;5(4).
          doi: 10.3390/pathogens5040064pubmed: 27897990google scholar: lookup
        13. Paillot R. A Systematic Review of Recent Advances in Equine Influenza Vaccination. Vaccines (Basel) 2014 Nov 14;2(4):797-831.
          doi: 10.3390/vaccines2040797pubmed: 26344892google scholar: lookup
        14. Francica JR, Sheng Z, Zhang Z, Nishimura Y, Shingai M, Ramesh A, Keele BF, Schmidt SD, Flynn BJ, Darko S, Lynch RM, Yamamoto T, Matus-Nicodemos R, Wolinsky D, Nason M, Valiante NM, Malyala P, De Gregorio E, Barnett SW, Singh M, O'Hagan DT, Koup RA, Mascola JR, Martin MA, Kepler TB, Douek DC, Shapiro L, Seder RA. Analysis of immunoglobulin transcripts and hypermutation following SHIV(AD8) infection and protein-plus-adjuvant immunization. Nat Commun 2015 Apr 10;6:6565.
          doi: 10.1038/ncomms7565pubmed: 25858157google scholar: lookup
        15. Bryant NA, Paillot R, Rash AS, Medcalf E, Montesso F, Ross J, Watson J, Jeggo M, Lewis NS, Newton JR, Elton DM. Comparison of two modern vaccines and previous influenza infection against challenge with an equine influenza virus from the Australian 2007 outbreak. Vet Res 2010 Mar-Apr;41(2):19.
          doi: 10.1051/vetres/2009067pubmed: 19863903google scholar: lookup
        16. Chambers TM, Quinlivan M, Sturgill T, Cullinane A, Horohov DW, Zamarin D, Arkins S, García-Sastre A, Palese P. Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses. Equine Vet J 2009 Jan;41(1):87-92.
          doi: 10.2746/042516408x371937pubmed: 19301588google scholar: lookup
        17. Elliott S, Olufemi OT, Daly JM. Systematic Review of Equine Influenza A Virus Vaccine Studies and Meta-Analysis of Vaccine Efficacy. Viruses 2023 Nov 28;15(12).
          doi: 10.3390/v15122337pubmed: 38140577google scholar: lookup
        Subscribe to our newsletter
        Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.